MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Eye, Ocular, Optometry, Ophthalmology, Vision Health Companies
STAAR Surgical Company (NASDAQ:STAA)*
Organization & Developments: Staar Surgical
Parents
STAAR Surgical Company (NASDAQ:STAA)*
Children
*STAAR designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems.
*The biocompatible implantable lenses are used to treat myopia and myopia with astigmatism.
*These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses.
*With the acquisition, Alcon brings in the Staar family of Evo Implantable Collamer lenses (ICLs). These lenses offer vision correction for patients with moderate-to-high myopia (nearsightedness), with or without astigmatism.
2021: Staar Surgical: Recent Bull Run Is Over, But Buying The Dip Advisable
2022: Keep Adding To STAAR Surgical Longs, Buy Thesis Remains_seekingalpha.com
2022: Staar Surgical wins FDA approval for Evo Visian implantable Collamer lens
2022: STAAR Surgical: Reasonable Risk-Reward For A High-Growth Company_ seekingalpha.com
2023: STAAR Surgical: Not In My Sight Yet
2023: STAAR Surgical: Slowly Coming In My Sight_ seekingalpha.com
2024: A Dive into Staar Surgical (STAA) International Revenue Trends and Forecasts
2024: Demand Fuels Expansion of STAAR Surgical’s Experience Center
2024: STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
2024: STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade
2024: STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge
2024: STAAR Surgical: Turning A Blind Eye
2025: STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Jumps
Finance & Acquisitions: Staar Surgical
Key People: Staar Surgical